Submissions for variant NM_000256.3(MYBPC3):c.3628-41_3628-17del

dbSNP: rs36212066

Total submissions: 13

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000158391	SCV000203933	likely benign	not specified	2020-08-14	criteria provided, single submitter	clinical testing	The c.3628-41_3628-17del variant in MYBPC3 has been identified in 3.2% (981/30592) of South Asian chromosomes, including 19 homozygotes, by gnomAD (http://gnomad.broadinstitute.org). This variant has been previously considered to be a common low-penetrance variant associated with milder, late-onset HCM in the heterozygote state, or early-onset disease in an autosomal recessive manner (Dhandapany 2009 PMID: 19151713, Waldmuller 2003 PMID: 12788380, Tanjore 2008 PMID: 18273486, Bashyam 2012 PMID: 21959974). A recent report has shown that this variant is not directly associated to cardiomyopathy but rather is in tight linkage disequilibrium with a rare intronic pathogenic MYBPC3 variant (c.1224-52G>A) that is reported to be one of the most frequent pathogenic variants associated to HCM in both Europeans and South Asians (Harper 2020 PMID: 32163302). Thus, the risk previously attributed to this variant can be explained by the intronic c.1224-52G>A variant. In summary, this variant is classified as likely benign. ACMG/AMP Criteria applied: BS1, BP2.
GeneDx	RCV002223792	SCV000208326	likely benign	not provided	2024-02-02	criteria provided, single submitter	clinical testing	See Variant Classification Assertion Criteria.
Bioinformatics dept., Datar Cancer Genetics Limited, India	RCV000495611	SCV000579489	likely pathogenic	Left ventricular noncompaction 10	2017-06-22	criteria provided, single submitter	clinical testing
Labcorp Genetics (formerly Invitae), Labcorp	RCV000527487	SCV000623601	pathogenic	Hypertrophic cardiomyopathy	2024-01-22	criteria provided, single submitter	clinical testing	This sequence change falls in intron 32 of the MYBPC3 gene. It does not directly change the encoded amino acid sequence of the MYBPC3 protein, but it does affect the splicing branch point of the intron (PMID: 12788380). RNA analysis indicates that this variant induces altered splicing and likely disrupts the C-terminus of the protein. This variant is present in population databases (rs36212066, gnomAD 3%), and has an allele count higher than expected for a pathogenic variant. This intronic sequence change is a founder variant in the South Asian population, and is found at a frequency of 3% (PMID: 24327208). A study of 28 families containing a total of 120 individual carriers of this sequence change observed that more than 90% of the oldest members of each family were symptomatic even though most young and middle-aged individuals were either asymptomatic or had mild hypertrophy (PMID: 19151713). This study found an approximately 7-fold increased risk for heart failure in carriers of this allele (PMID: 19151713). Individuals with two copies of the c.3628-41_3628-17del variant (homozygous), or a single copy of this variant with a different pathogenic variant, may develop a more severe and early-onset cardiomyopathy than individuals with a single copy of the variant (PMID: 19151713, 32543992). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 177677). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects MYBPC3 function (PMID: 19151713). Studies have shown that this variant results in skipping of exon 33 and introduces a new termination codon (PMID: 12788380, 24327208). However the mRNA is not expected to undergo nonsense-mediated decay. A recent study suggested that individuals with this variant will not develop HCM because a single copy of the c.3628-41_3628-17del variant is frequently observed in individuals without cardiomyopathy (PMID: 32163302). However, based on the collective studies identifying an association with late-onset cardiomyopathy or heart failure and functional studies that support the c.3628-41_3628-17del variant changes the normal function of the MYBPC3 protein (PMID: 32656747, 32543992), this sequence change has been classified as Pathogenic.
Agnes Ginges Centre for Molecular Cardiology, Centenary Institute	RCV000527487	SCV000996366	uncertain significance	Hypertrophic cardiomyopathy	2017-02-08	criteria provided, single submitter	research	This variant has been identified as part of our research program. Refer to the 'condition' field for the phenotype of the proband(s) identified with this variant. For further information please feel free to contact us.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario	RCV001170948	SCV001333600	uncertain significance	Cardiomyopathy	2023-06-02	criteria provided, single submitter	clinical testing
Color Diagnostics, LLC DBA Color Health	RCV001170948	SCV001355390	likely benign	Cardiomyopathy	2020-03-24	criteria provided, single submitter	clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000158391	SCV001448489	benign	not specified	2021-03-12	criteria provided, single submitter	clinical testing	Variant summary: MYBPC3 c.3628-41_3628-17del25 (also reported as the MYBPC3 delta25 variant) alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 4/4 computational tools predict no significant impact on normal splicing. In contrast, early publications demonstrated that the variant affects normal splicing leading to skipping of exon 33 and a loss of 62 amino acids that modified the C10 domain of the MYBPC3 protein (Waldmuller_2003, Dhandapany_2009). However, both residual normally spliced and deleted transcripts were reported in these studies, therefore the exact in-vivo consequence of this finding remains questionable in light of additional reports summarized below. The variant allele was found at a frequency of 0.004 in 250036 control chromosomes, predominantly at a frequency of 0.032 within the South Asian subpopulation in the gnomAD database, including 19 homozygotes. The observed variant frequency within South Asian control individuals in the gnomAD database is approximately 32 fold of the estimated maximal expected allele frequency for a pathogenic variant in MYBPC3 causing Hypertrophic Cardiomyopathy phenotype (0.001), strongly suggesting that the variant is a benign polymorphism found primarily in populations of South Asian origin. c.3628-41_3628-17del25 has been reported in the literature predominantly in studies of South Asian individuals affected with Hypertrophic Cardiomyopathy (example, Waldmuller_2003, Tanjore_2008, Dhandapany_2009, Alfares_2015, Harper_2020). In a conservative ascertainment of families reported with this variant, we captured 7 transmissions of the variant allele and 5 transmissions of the reference allele to affected individuals (Waldmuller_2003, Tanjore_2008) suggestive of lack of segregation with disease. A recent study reported that the risk of HCM previously attributed to this 25-base pair deletion is explained by a linkage disequilibrium between this deletion and another deep intronic MYBPC3 variant, c.1224-52G>A which is causative of HCM (Harper_2020). Direct comparison of the proportion of heterozygous MYBPC3 delta25 variant carriers between the HCMR (17/134) and gnomAD (943/15 296) South Asian cohorts indicated a 2-fold enrichment within HCM cases (odds ratio [OR], 2.1 [95% CI, 1.2-3.4]; P=0.008). When HCMR probands with the MYBPC3 delta25/52 haplotype were excluded, no difference was observed (OR, 0.96 [95% CI, 0.40-1.95]; P=1.0). Therefore, these data do not allow any conclusion about the significance of c.3628-41_3628-17del25 in isolation. Multiple co-occurrences with other pathogenic variant(s) have been reported, example, PRKAG2 c.905G>A, p.Arg302Gln (Alfares_2015); MYBPC3 c.1224-52G>A; MYBPC3 c.2827C>T, p.Arg943*; MYBPC3 c.821+2T>C (Harper_2020), providing additional supporting evidence for a benign role. At least one publication reports experimental evidence evaluating an impact on protein function in a mice model. The most pronounced variant effect results in an HCM phenotype in mice at 12 weeks of age and mislocalization of the mutant protein to the sarcomere resulting in its categorization as an at-risk allele for heart failure and adverse cardiovascular outcomes (Kuster_2019, Sadayappan_2020). However, in the context of our ascertainment, when objectively ascertained for the degree of reported contractile dysfunction and HCM in vivo attributed to this variant, the evidence as reported is not translatable to an in-vivo impact in humans (Kuster_2019). Eight clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (pathogenic, n=1; likely pathogenic, n=4, VUS, n=2; benign, n=1). Some submitters cite overlapping but not all the recently published evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant in isolation (MYBPC3 delta25) without the c.1224-52G>A variant, was re-classified as benign.
AiLife Diagnostics, AiLife Diagnostics	RCV002223792	SCV002502816	pathogenic	not provided	2022-02-22	criteria provided, single submitter	clinical testing
Mendelics	RCV001254179	SCV002517748	likely benign	Hypertrophic cardiomyopathy 4	2024-10-31	criteria provided, single submitter	clinical testing	The NM_000256.3(MYBPC3):c.3628-41_3628-17del variant (rs36212066) has a GnomAD 4.1.0 frequency of 0.001855 (2992 heterozygotes) with 67 homozygotes. This frequency and the number of homozygotes are not compatible to a variant causing the disease.
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute	RCV001170948	SCV005399301	uncertain significance	Cardiomyopathy	2020-06-11	criteria provided, single submitter	clinical testing	Based on the classification scheme VCGS_Germline_v1.1.1, this variant is classified as 3C-VUS. Following criteria are met: 0102 - Loss-of-function is a known mechanism of disease for this gene. (N) 0108 - This gene is known to be associated with both recessive and dominant disease. Heterozygous variants are frequently reported in adult onset conditions, however, recessive inheritance results in a more severe early onset phenotype (OMIM). (N) 0205 – Intronic deletion variant that is predicted to result in a splicing and a truncated protein, with less than 1/3 of the protein affected. (P) 0210 - Splice site variant (canonical or non-canonical) proven to affect splicing/expression of the transcript with a known effect on protein structure. Sequencing of the mRNA from carriers of this variant demonstrated exon 33 skipping. (N) 0251 - Variant is heterozygous. (N) 0308 - Population frequency for this variant in gnomAD is out of keeping with known incidence of cardiomyopathy (962 heterozygotes, 19 homozygotes). (B) 0701 - Comparable variants have very strong previous evidence for pathogenicity. Multiple truncating variants have been reported downstream of this variant (ClinVar). (P) 0801 - Strong previous evidence of pathogenicity in unrelated individuals. More than 10 heterozygotes and homozygotes with cardiomyopathy have been reported with this variant. However, the homozygous deletion was also found in normal individuals (PMID: 19151713). (P) 1002 - Moderate functional evidence supporting abnormal protein function. Expression of this variant in neonatal rat cardiomyocytes highly disorganized and diffused pattern of sarcometric architecture and expression of a protein with lower molecular weight (PMID: 19151713). (P) 1208 - Inheritance information for this variant is not currently available. (N) Legend: (P) - Pathogenic, (N) - Neutral, (B) - Benign
Clinical Genomics Laboratory, Stanford Medicine	RCV001254179	SCV001427228	likely pathogenic	Hypertrophic cardiomyopathy 4	2020-03-12	no assertion criteria provided	clinical testing	The c.3628-41_3628-17del25 variant in the MYBPC3 gene has been previously reported in the heterozygous, compound heterozygous, or homozygous state in >30 unrelated individuals with cardiomyopathy (Alfares et al., 2015; Bashyam et al., 2012; Dhandapany et al., 2009; Waldmuller et al., 2003). The c.3628-41_3628-17del25 variant has also been identified in 981/30,592 South Asian chromosomes, including 19 homozygotes, by the Genome Aggregation Database (http://gnomad.broadinstitute.org/), indicating it may be a common, reduced penetrance allele in this population. While the c.3628-41_3628-17del25 variant is relatively common in individuals of South Asian ancestry, case-control studies have found an associated risk with cardiomyopathy (Dhandapany et al., 2009). This variant is predicted to disrupt splicing and lead to skipping of exon 33, reducing the length of the protein (Dhandapany et al., 2009; Waldmuller et al., 2003). These data were assessed using the ACMG/AMP variant interpretation guidelines. In summary, there is sufficient evidence to classify the c.3628-41_3628- 17del25 variant as likely pathogenic with reduced penetrance for hypertrophic cardiomyopathy in an autosomal dominant manner based on the information above. [ACMG evidence codes used: PS4; PM4]
PreventionGenetics, part of Exact Sciences	RCV004551330	SCV004729665	benign	MYBPC3-related disorder	2020-04-07	no assertion criteria provided	clinical testing	This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).